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Abstract
Background: Sci-B-Vac™ is a recombinant, hepatitis B vaccine derived from a mammalian cell line
and containing hepatitis B surface antigen (HBsAg) as well as preS1 and preS2 antigens. Few studies
have been performed on the antibody responses to preS1 in relation to the antibody to hepatitis
B surface antigen (anti-HBs) response during immunisation of healthy children with preS-containing
vaccines.
Results: In this study 28 healthy newborns were randomly selected to receive either 2.5 ug or 5.0
ug of the Sci-B-Vac vaccine. Children received three doses of vaccine according to a 0-, 1-, 6-month
scheme. Antibodies against the S-protein and three synthetic peptides mimicking three B-cell preS1
epitopes, (21–32 amino acid epitope), (32–47 amino acid epitope) and the C-terminal (amino acid
epitope 94–117) were determined at 6 and 9 months. Fourteen (50%) of the 28 newborns had
detectable levels of anti-preS1 (21–32) antibodies; 15 (54%) were anti-preS1 (32–47) reactive and
12 (43%) were anti-preS1 (94–117) reactive at 6 or 9 months after initiation of the vaccination.
Significantly higher levels of anti-HBs were observed in the sera of patients with detectable anti-
preS1 (32–47) reactivity (24 550 ± 7375 IU/L, mean ± SEM) as compared with the non-reactive sera
(5991 ± 1530 IU/L, p < 0.05). The anti-HBs levels were significantly lower if none (p < 0.05) or one
(p < 0.025) of the preS1 (21–32, 32–47, 94–117) peptides were recognised compared with the anti-
HBs levels if two or three peptides were recognised.
Conclusion: Recognition of several preS1 epitopes, and in particular, the epitope contained within
the second half of the hepatocyte binding site localised in the hepatitis B surface protein of the
third-generation hepatitis B vaccine is accompanied by a more pronounced antibody response to
the S-gene-derived protein in healthy newborns.
Background
Infectious particles of hepatitis B virus (HBV), called Dane
particles, consist of viral nucleic acid encapsulated within
a core particle enveloped by three distinct virus-coded sur-
face proteins. These three proteins, termed preS1, preS2
and S, are co-terminal at the C-terminus but are different
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at the N-terminus end regarding the position of the initi-
ation codon of protein translation of the viral genome [1].
It has been demonstrated that the C-terminal part of the
preS1 region is essential for viral assembly [2] whereas the
N-terminal part is believed to play a major role in mediat-
ing virus attachment and entry into hepatocytes [3].
Within the preS1 protein, the 21–47 amino acid epitope
was shown to mediate binding to the cell surface of
HepG2 cells [4]. Antibodies directed against this epitope
were shown to have virus-neutralising activity [5]. A
polypeptide covering the N-terminal region 21–47 could
inhibit virus-cell interactions, as does the antibody against
this fragment [6-8]. Moreover, the hepatitis B surface anti-
gen(HBsAg) preS1 region is highly immunogenic, con-
taining both sequential and conformational epitopes [9]
with abundant T- and B-cell epitopes [10-15].
Thus, multiple viral functions of the preS1 region provide
a useful target for anti-HBV intervention. Recombinant
preS products have been developed as protein vaccines
that elicit B- and T-cell immune responses on a broader
range of major histocompatibility complex (MHC) haplo-
types [16-19]. Comparative immunogenicity studies in
mice, rabbits and humans using one such vaccine (Bio-
Hep B/Sci-B-Vac™, also known as Hepimmune) have
repeatedly confirmed the excellent immunogenicity
measured as antibody to hepatitis B surface antigen (anti-
HBs) production and safety of this third-generation HBV
vaccine [20]. However, only a few studies have been per-
formed on the antibody responses to preS1 in relation to
the anti-HBs response during immunisation of healthy
children with preS-containing vaccines.
Recently, we demonstrated that recognition of the preS
epitopes contained in the third-generation preS1/preS2/S
vaccine (Sci-B-Vac™, BioHepB) is accompanied by a more
rapid onset and pronounced antibody response to the S-
gene-derived protein in healthy children and newborns
[21,22]. To further analyse the specificity and significance
of the antibody responses toward the two linear preS1
sequences that have been shown to represent human B
cell epitopes within the hepatocyte binding site compris-
ing amino acids preS1 (21–47) [[4,6,7], reviewed in [23]],
as well as the C-terminal part comprising amino acids
(94–117) [24,25], we measured the specific antibody
response in healthy newborns after immunisation with
the Sci-B-Vac™ vaccine. Furthermore, we evaluated
whether induction of antibodies toward the three preS1
epitopes (21–32, 32–47 and 94–117) is associated with
an enhanced response to HBsAg. We found that recogni-
tion of several preS1 epitopes, and in particular, the
epitope contained within the second half of the hepato-
cyte binding site localised in the hepatitis B surface pro-
tein of the third-generation hepatitis B vaccine is
accompanied by a more pronounced antibody response
to the S-gene-derived protein in healthy newborns.
Methods
Vaccine
Immunisation of newborns was performed with the
recombinant Chinese hamster ovary (rCHO) cell-derived
Sci-B-Vac™ vaccine, (SciGen Ltd, Singapore, earlier
referred to as Bio-Hep-B™ vaccine, Bio-Technology Gen-
eral Corporation) [19]. The vaccine was purified from the
culture media of CHO cells transfected with the nucle-
otide sequences coding for all three surface antigens (i.e.
preS1, preS2 and S). The Sci-B-Vac™ vaccine of the HBsAg
subtype adw2 and genotype A is > 99% pure and the pro-
teins of the vaccine are absorbed on alum phosphate (0.5
mg/ml); the preservative agent is Thiomerosal (50 ug/ml).
The vaccine was stored and transported at 2–8°C. The
same batch of vaccine was used throughout the study. The
vaccinees received three doses of vaccine according to a 0-
, 1-, and 6-month schedule [21].
Study design
Twenty-eight healthy newborns were qualified for vacci-
nation. Fifteen received 2.5 ug doses and 13 received 5.0
ug doses of vaccine. The selection of infants was random.
The mothers were negative for hepatitis B markers
(HBsAg, antibody to hepatitis B core antigen (anti-HBc)
and anti-HBs). The cord blood samples were also negative
for these markers. The transaminase levels (ALT) in
mother and cord blood samples were within the normal
range. The newborns were evaluated within the first 5 min
of life as having at least 7 points on the Apgar scale. The
newborns' body weight was > 2500 g. Newborns from
drug-addicted or alcoholic parents were excluded from
the study. Anti-HBs and anti-preS1 antibodies were evalu-
ated at 6 (T6, i.e. 5 months after the second injection) and
9 months (T9, i.e. 3 months after the third injection) after
vaccination with the Sci-B-Vac™ vaccine.
In accordance with the Helsinki declaration, parents of all
children had signed an informed consent form for partic-
ipation in the study, The parents were instructed on how
the vaccine was tested for safety and immunogenicity in
adults and how to observe local signs and general symp-
toms associated with the vaccine administration. The fre-
quencies of all signs and symptoms (i.e. vaccine reactions)
that the parents observed were reported in their diary
cards. These signs might include appetite loss, diarrhoea,
fever, irritability, sleeplessness and vomiting, as well as
the local signs of pain and redness or swelling at the injec-
tion site. The study was approved by the Ethics Committee
of the Child health Memorial Institute [21].Virology Journal 2009, 6:7 http://www.virologyj.com/content/6/1/7
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Antibody detection
Anti-HBs antibodies were measured using a microparticle
enzyme immunoassay in an IMX apparatus (Abbott, Chi-
cago, ILL., USA) and expressed as IU/L. Control tests (hep-
atitis B, anti-HBs from Labquality, Helsinki, Finland) were
used throughout the study. Antibodies to preS1 were
assessed by enzyme-linked immunosorbent assay
(ELISA). Microtitreplates (Immunolon 2, no.011-010-
3455, Dynatech, Chantilly, VA, USA) were coated with
preS1 (21–32), (32–47), (94–117) (adw2) peptídes (pur-
chased from Sigma Genosys, Cambridge, UK) at a concen-
tration of 2 ug/ml in 0.05 M sodium carbonate buffer (pH
9.6) at 4°C overnight.
Patient and pooled control sera, diluted 1/125 in 0.05 M
phosphate-buffered saline (PBS)-Tween-1% foetal bovine
serum (FBS), were incubated on the plates at 4°C over-
night. The plates were washed and incubated with alka-
line phosphatase (ALP)-conjugated goat anti-human
gamma chains (A-3187, Sigma Chemical Company, St.
Louis, MO, USA) and diluted 1:1000 in PBS-Tween-1%
FBS at 4°C overnight. After incubation (5–30 min) with
p-nitrophenyl phosphate in diethanolamine HCl, the
optical density (OD) at 405 nm was measured in a Titer-
tek Multiskan Plus Photometer (Flow Laboratories, Edin-
burgh, Scotland). Sera from 20 hepatitis B-susceptible
healthy blood donors, routinely tested and lacking serum
markers for hepatitis A-E, were pooled and used as con-
trols to obtain the normal (N) value. Positive antibody
reactivity was defined as a sample (S) over the N value (S/
N ≥ 2.5) equal to the mean OD value plus 4 SD of the con-
trol sample.
Specificity tests
Equal volumes of diluted serum samples from anti-preS1
(21–32) or (32–47) reactive individuals and inhibitors
(0.125–8.0 ug/mL) were incubated for 4 h at 4°C before
addition to the ELISA plates and further analysed as
described above. The synthetic peptide analogues preS1
adw2 (21–32), (32–47) or (94–117) were used as inhibi-
tors. The relevant preS1 peptide inhibited the preS1 reac-
tivity to 100% whereas irrelevant preS1 peptides did not
(Figures 1 and 2). Anti-preS1 (94–117) specificity has
been documented earlier [25].
Statistical analysis
The non-parametric Mann-Whitney U test was employed
to compare data between groups of newborns vaccinated
with different doses of the Sci-B-Vac™ vaccine.
Results
The presence of IgG antibodies with specificity for the syn-
thetic peptide analogues corresponding to the preS1 (21–
32), (32–47) and (94–117) regions of the HBV was stud-
ied using peptide-based ELISA at a 1/125 dilution of sera
from 28 newborns after complete immunisation with the
Sci-B-Vac™ vaccine. Fourteen (50%) of the 28 newborns
had detectable levels of anti-preS1 (21–32) antibodies at
6 or 9 months after initiation of the vaccination. Fifteen
(54%) and 12 (43%) newborns were anti-preS1 (32–47)
and (94–117) reactive, respectively. No significant differ-
ence in response to the preS1 epitopes was noted in new-
borns immunised with the 2.5 ug or the 5.0 ug vaccine
doses.
The mean levels of anti-HBs were significantly higher in
the anti-preS1 (32–47) reactive sera (24 550 ± 7375 IU/L,
mean ± SEM) as compared with the non-reactive sera
(5991 ± 1530 IU/L, p < 0.05) (Table 1). In contrast, no sig-
nificant difference was noted between anti-preS1 (21–32)
or (94–117) reactive group compared with their respec-
tive non-reactive groups.
Table 2 demonstrates that the anti-HBs levels were signif-
icantly lower if none (p < 0.05) or one (p < 0.025) of the
preS1 (21–32, 32–47, 94–117) peptides were recognised
in comparison with the anti-HBs levels if two or three pep-
tides were recognised.
Discussion
A large number of studies have suggested a direct involve-
ment of the preS1 domain of the hepatitis B virus large
envelope protein (L-HBsAg) (in particular amino acids 21
to 47) in a virus attachment to hepatocytes [[4,6,7],
reviewed in [23]]. Recently, it was demonstrated that a
mutant L-HBsAg bearing a deletion in the 26–30 amino
acid sequence of the preS1 receptor binding site was non-
infectious and hence deficient in viral entry [3], further
supporting the importance of this domain as an infectivity
determinant in hepatitis B. The aim in this study was to
identify preS1 antibodies reacting with two human anti-
body binding sites, p (21–32), containing an infectivity
determinant and p (32–47), including a previously
defined HBV-neutralisation epitope comprising amino
acids 37–45 of preS1 that have been identified within this
sequence [26] as well as preS1 antibodies reacting with
the C-terminal part (94–117) in sera from newborns com-
pletely immunised with the third-generation recom-
binant vaccine (Sci-B-Vac™).
We found that immunised newborns exhibited anti-preS1
(21–32) and anti-preS1 (32–47) and anti-preS1 (94–117)
antibody reactivity in 50% (14/28), 54% (15/28) and
43% (12/28), respectively. The prevalence of vaccine-
induced anti-peptide antibodies in this study is identical
to the prevalence of antibodies reacting with p (21–32), p
(32–47) and p (94–117) in sera obtained during conva-
lescence from natural HBV infection [24]. The third-gen-
eration vaccine used in this study, Sci-B-Vac™, was
developed using mammalian cells, which provide enve-Virology Journal 2009, 6:7 http://www.virologyj.com/content/6/1/7
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lope proteins similar to those isolated from infected
patients and used for preparation of some of the first-gen-
eration HBV vaccines [20]. This similarity could explain
the identical immunogenicity and specificity induced by
natural infection or complete vaccination with a preS1-,
preS2- and S-containing hepatitis B vaccine.
Five of 28 (18%) newborns lacked detectable levels of
anti-preS1 (21–32), anti-preS1 (32–47) or anti-preS1
(94–117) antibodies. One explanation for this observa-
tion could be that the preS1 (21–32; 32–47 and 94–117)
non-reactive patients have conformation dependent anti-
preS1 antibodies in the circulation that are not reactive
with the linear peptide analogues of preS1 (21–32, 32–47
and 94–117) used in this study. In most cases synthetic
peptides are considered unsuitable for studying the dis-
continuously conformational epitopes because most pep-
tide-specific antibodies are continuous sequence-specific
[27]. The three-dimensional structure of the HBV surface
protein, including preS1, has not yet been determined,
though Lian et al [28] recently demonstrated that amino
acids 31–36 were pivotal for the folding and conforma-
tional stability of the preS protein.
We demonstrated that those newborns that developed
antibody reactivity against two or three B-cell epitopes
had a significantly stronger anti-HBs response than those
individuals that showed a narrower preS1 response. In
Inhibition of IgG anti-preS1(21–32) reactivity Figure 1
Inhibition of IgG anti-preS1(21–32) reactivity. A diluted serum sample from an anti-preS1 (21–32) reactive patient was 
preincubated with different concentrations (0.125–8.0 ug/mL) of the synthetic peptide analogue corresponding to the (black 
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congenic mice inclusion of preS regions elicits a broader
spectrum of protective antibodies that augment the anti-
HBs response and circumvent non-responsiveness to the S
protein [26].
The preS1 region in humans has been shown to be a par-
ticularly efficient immunogen at the T-cell level. A domi-
nant T-cell recognition site was identified in the N-
terminal residues 21–28 (serotype adw) of the preS1
sequence [29,30] and in vitro binding studies have
defined preS1 (25–33) as a promising helper T-cell
epitope [31]. Further studies will show whether preS1 T-
Inhibition of IgG anti-preS1 (32–47) reactivity Figure 2
Inhibition of IgG anti-preS1 (32–47) reactivity. A diluted serum sample from an anti-preS1 (32–47) reactive patient was 
preincubated with different concentrations (0.125–8.0 ug/mL) of the synthetic peptide analogue corresponding to the (black 
circle) 21–32, (black square) 32–47 or (black rhomboid) 94–117 amino acid sequences of preS1 before assaying in the preS1 
(32–47) ELISA.
Table 1: Anti-HBs titres in preS1 (21–32, 32–47 and 94–117) 
reactive sera compared with non-reactive sera from newborns 
vaccinated with Bio-HepB™ vaccine
Reactive Non-reactive Probability
Anti-preS1 (21–32) n = 14 n = 14
Anti-HBs IU/L 15 841 ± 4 023 16 026 ± 7 859 ns
Anti-preS1 (32–47) n = 15 n = 13
Anti-HBs IU/L 24 550 ± 7 375 5 991 ± 1 530 p < 0.05
Anti-preS1 (94–117) n = 12 n = 16
Anti-HBs IU/L 19 464 ± 5 280 13 286 ± 6 533 ns
ns = not significant
Anti-HBs (mean ± SEM)
Table 2: Anti-HBs levels in vaccinated newborns with different 
anti-preS1 peptide (21–32, 32–47, 94–117) reactivities at time 
T9
Reactivity with Number Anti-HBs (IU/L) Probability*
3 preS1 peptides n = 7 23 688 ± 6 183 a/
2 preS1 peptides n = 4 22 890 ± 10 670 b/ ns
1 preS1 peptide n = 12 11 919 ± 8 669 c/ p < 0.025
0 preS1 peptide n = 5 2 065 ± 1 105 d/ p < 0.05
*the a/ compared with the b/, c/ or d/ groups of vaccinated newborns 
(Mann-Whitney test)
ns = not significant
T9 = three months after the third injection
Anti-HBs (mean ± SEM)Virology Journal 2009, 6:7 http://www.virologyj.com/content/6/1/7
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cell epitopes contained within the third-generation hepa-
titis B vaccine can mediate helper T-cell functions on the
human antibody response to the particulate HBsAg simi-
larly to what has been shown in the mouse system.
List of abbreviations
HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen;
Anti-HBc: antibody to hepatitis B core antigen; Anti-HBs:
antibody to hepatitis B surface antigen; ALT: alanine ami-
notransferase; OD: optical density; N: normal; S: sample.
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